Teriparatide: Dosing Protocols
Dosing guidelines, reconstitution, and administration information
๐TL;DR
- โข1 dosing protocols documented
- โขReconstitution instructions included
- โขStorage: Store refrigerated at 2-8 degrees C (36-46 degrees F) at all times. Do not freeze. Do not use if the solution has been frozen. The pen may be used for up to 28 days after first injection. Recap pen after each use to protect from light.
Protocol Quick-Reference
Osteoporosis in postmenopausal women, men, and GIO patients at high fracture risk
Dosing
Amount
20 mcg fixed dose
Frequency
Once daily
Duration
Determined by clinical judgment (no limit)
Administration
Route
SCSchedule
Once daily
Timing
Same time each day; no food restrictions
โ Rotate injection sites
Cycle
Duration
Determined by clinical judgment
Repeatable
Yes
Preparation & Storage
โ Ready-to-use โ no reconstitution required
Storage: Refrigerate at 2-8 degrees C at all times. Do not freeze. Pen usable for 28 days after first injection.
โ๏ธ Suggested Bloodwork (5 tests)
Serum calcium
When: Baseline
Why: Rule out pre-existing hypercalcemia
25-hydroxyvitamin D
When: Baseline
Why: Ensure adequate vitamin D before treatment
DEXA bone density scan
When: Baseline
Why: Establish baseline BMD at spine and hip
Serum calcium
When: Periodic
Why: Monitor for hypercalcemia
DEXA bone density scan
When: 12-24 months
Why: Assess BMD response
๐ก Key Considerations
- โFollow with antiresorptive therapy after discontinuation to consolidate BMD gains
- โEnsure adequate calcium and vitamin D supplementation
- โContraindicated in Paget disease, unexplained elevated ALP, open epiphyses, prior skeletal radiation, and pre-existing hypercalcemia
Unlock dosing protocols
Free access to research-backed dosing information for all peptides.
150+ peptide profiles ยท 30+ comparisons ยท 18 research tools
| Purpose | Dose | Frequency | Duration | Notes |
|---|---|---|---|---|
| Osteoporosis (Postmenopausal, Male, and Glucocorticoid-Induced) | 20 mcg subcutaneous injection once daily. Fixed dose for all patients and all approved indications. No dose titration required. | Once daily subcutaneous injection | No longer limited to 2 years (boxed warning removed 2020). Treatment duration determined by clinical judgment. Should be followed by antiresorptive therapy to maintain BMD gains. | No dose adjustment required for age, body weight, mild-moderate renal impairment, or hepatic impairment. Calcium and vitamin D supplementation recommended. Administer where patient can sit or lie down if dizziness occurs. |
Unlock full dosage protocols
Free access to complete dosing tables and protocol details.
150+ peptide profiles ยท 30+ comparisons ยท 18 research tools
๐Reconstitution Instructions
Teriparatide (Forteo) is supplied as a pre-filled pen device containing 2.4 mL of solution (600 mcg total), delivering 28 daily doses of 20 mcg each. No reconstitution, mixing, or dilution is required. Biosimilar versions may have different pen configurations.
Recommended Injection Sites
- โThigh (anterior, middle third)
- โAbdominal wall (periumbilical area)
๐งStorage Requirements
Store refrigerated at 2-8 degrees C (36-46 degrees F) at all times. Do not freeze. Do not use if the solution has been frozen. The pen may be used for up to 28 days after first injection. Recap pen after each use to protect from light.
Community Dosing Protocols
Compare these clinical doses with what 80+ community members report using.
Based on 80+ community reports
View community protocolsResearch Tools
Before You Begin
Review safety warnings and contraindications before starting any protocol.
Prescribing Information#
Teriparatide (Forteo) is an FDA-approved prescription medication for the treatment of osteoporosis in postmenopausal women, men with primary or hypogonadal osteoporosis, and men and women with glucocorticoid-induced osteoporosis at high risk for fracture. All dosing information is based on FDA-approved prescribing information and clinical trial protocols. Teriparatide must be prescribed and supervised by a qualified healthcare provider.
Dosing Protocol#
Fixed Dose#
Teriparatide is administered as a fixed 20 mcg dose once daily by subcutaneous injection. The dose is the same for all approved indications and requires no titration.
Treatment Duration#
Following the FDA's 2020 removal of the osteosarcoma boxed warning and 2-year treatment limitation, treatment duration is no longer restricted. Duration should be determined by clinical judgment based on fracture risk, BMD response, and the availability of alternative therapies.
Sequential Therapy#
Discontinuation of teriparatide without transition to an antiresorptive agent results in rapid BMD decline. Sequential therapy with a bisphosphonate (alendronate, zoledronic acid) or denosumab is recommended to consolidate and maintain the bone gained during anabolic treatment.
| Treatment Phase | Agent | Duration | Purpose |
|---|---|---|---|
| Anabolic phase | Teriparatide 20 mcg daily | Per clinical judgment | Build new bone |
| Consolidation | Bisphosphonate or denosumab | Ongoing | Maintain BMD gains |
Administration Technique#
Pre-Filled Pen Device#
Forteo is supplied as a pre-filled, disposable pen containing 2.4 mL of teriparatide solution (250 mcg/mL, 600 mcg total), delivering 28 doses of 20 mcg each. The pen uses disposable needles (29-gauge).
Injection Procedure#
-
Preparation: Remove pen from refrigerator. Do not warm to room temperature (Forteo must remain refrigerated). Attach a new needle. For new pens, prime by pressing the injection button until a drop appears.
-
Site selection: Inject into the thigh or abdominal wall. Rotate injection sites daily.
-
Injection: Insert needle into pinched skin fold, press and release the black injection button, hold needle in skin for 6 seconds, then withdraw.
-
Disposal: Remove and dispose of needle in sharps container. Replace pen cap and return to refrigerator.
Timing and Missed Doses#
- Administer at approximately the same time each day
- No food or fasting requirements
- Patients may sit or lie down during and after injection if orthostatic symptoms occur
- If a dose is missed, administer as soon as possible that day. Do not double the dose.
Storage Requirements#
- Refrigeration required: Store at 2-8 degrees C (36-46 degrees F) at all times, including during use
- Do not freeze: Frozen teriparatide should not be used
- Light protection: Replace pen cap after each use
- Pen expiry: Discard 28 days after first injection, even if doses remain
- Travel: Use insulated carrying case with cold pack for transport
Unlike abaloparatide (which can be stored at room temperature after first use), teriparatide requires continuous refrigeration, which affects convenience for travel.
Special Dosing Considerations#
Renal Impairment#
No dose adjustment required for mild to moderate renal impairment. Not studied in severe renal impairment or dialysis; use with caution as PTH clearance may be reduced.
Hepatic Impairment#
No dose adjustment required. Hepatic metabolism is non-CYP mediated.
Elderly Patients#
No dose adjustment required. Clinical trials included patients over 65 with comparable efficacy.
Glucocorticoid-Induced Osteoporosis#
The same 20 mcg daily dose is used for GIO. In the Saag et al. trial, teriparatide was superior to alendronate for both BMD gains and vertebral fracture prevention in patients receiving chronic glucocorticoids.
Supplementation Requirements#
- Calcium: At least 1,000 mg daily (diet and supplements)
- Vitamin D: At least 400-800 IU daily; correct deficiency before initiating therapy
- Adequate vitamin D is essential for the osteoanabolic response to teriparatide
Monitoring Recommendations#
| Test | Timing | Purpose |
|---|---|---|
| Serum calcium | Baseline, periodic | Detect hypercalcemia |
| 25-hydroxyvitamin D | Baseline | Ensure adequate vitamin D |
| DEXA scan | Baseline, 12-24 months | Assess BMD response |
| Alkaline phosphatase | Baseline | Rule out Paget disease |
| Uric acid | Baseline | Teriparatide may increase uric acid |
Related Reading#
Subscribe to see vendor options
Free access to verified vendor scores, pricing, and suppliers.
150+ peptide profiles ยท 30+ comparisons ยท 18 research tools
Protocol updates
Get notified when we update dosing protocols or publish related comparisons.
Frequently Asked Questions About Teriparatide
Explore Further
Medical Disclaimer
This website is for educational and informational purposes only. The information provided is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before using any peptide or supplement.